safety-lane.com 07105
chiropractic-lane.com
www.shopcbd-lane
NEWARK
http://www.healthy-lane.com/
Endoscopic Sleeve Gastroplasty Plus Obesity Drugs Add Up to More Weight Loss
Anti-obesity medications and endoscopic sleeve gastroplasty (ESG) are popular strategies for weight loss on their own. Now researchers are looking at what happens when you combine them.
In a study presented at Digestive Disease Week (DDW) 2023, they found ESG followed by an anti-obesity medication led to more total weight loss than ESG alone.
Starting medication within 6 months of ESG was more ideal than other timing intervals. Initiating medical therapy more than 6 months before ESG was associated with less weight loss.
In the single-center, retrospective study, 224 patients were enrolled, of whom 34% were on monotherapy (ESG alone), 31% had combination therapy (medication prescribed within 6 months prior to or after ESG), and 35% had sequential therapy (medication more than 6 months prior to or after ESG).
Most patients were female, ranging from 74% to 95% of each group, and baseline BMI ranged from a mean 37.5 kg/m2 to 40.1 kg/m2.
The medications involved in the study were phentermine, phentermine/topiramate ER (Qsymia), orlistat (Xenical, Alli), bupropion/naltrexone ER (Contrave), or the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (Saxenda, Victoza) or semaglutide (Ozempic, Wegovy, Rybelsus). Of the patients who underwent combination therapy, 30% were prescribed a regimen that included a GLP-1RA. Of the patients who underwent sequential therapy, 81% were prescribed a medication first and 19% underwent ESG first.
At 1 year, the greatest total weight loss was a mean 23.7% with the combination of ESG and a GLP-1RA. Total weight loss was 18% with ESG plus a non-GLP-1RA medication. ESG alone led to 17.3%. Sequential therapy that began with ESG yielded 14.7% total weight loss, whereas sequential therapy that began with medication first resulted in 12% weight loss.
The serious adverse event (SAE) rate associated with ESG was similar among the three cohorts: 2.6% with monotherapy group, 1.4% with combination therapy, and 1.3% with sequential therapy. SAEs associated with anti-obesity medication occurred in 1.3% of the sequential therapy group and was not reported in either of the other two groups.
Digestive Disease Week (DDW) 2023. Abstracts 701 and 703.
Presented May 8, 2023.
via Blogger https://bit.ly/45jZiDN
Recent Comments